The Kimberly-Clark/Kenvue transaction is one of the worst-received major merger deals in recent years. Investors wondered why ...

The recent publicity could allow the company to get a good deal on Kenvue, which makes Tylenol, Band-Aids, and other ...

A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue ...

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for $48.7bn. One of America’s ...

Kimberly-Clark has demonstrated its ambitions in the consumer healthcare segment after agreeing to buy Neutrogena, Tylenol ...

Asian shares are trading mixed after overseas markets got a big lift from optimism over AI technology. Shares rose in Hong Kong on Tuesday, while slipping in Tokyo, Sydney and Seoul. On Wall ...

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling ...

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Under the agreement, each Kenvue Inc. (NYSE:KVUE) shareholder would receive $3.5 per share in cash as well as 0.14625 ...

While the canard that many mergers fail to provide a return to shareholders does not appear to be supported by the data, mergers still occur that appear to be motivated by little more than a CEO& ...